Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Trial Details

NCT ID

NCT05744687

Phase

PHASE2 / PHASE3

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• SPH4336 Tablets 400mg
• SPH4336 Tablets Placebo

Locations (sample)

• Fuzhou, Fujian, China|26.06139,119.30611
• Guangzhou, Guangdong, China|23.11667,113.25
• Guiyang, Guizhou, China|26.58333,106.71667
• Anyang, Henan, China|36.096,114.38278
• Luoyang, Henan, China|34.67345,112.43684

Key Eligibility Criteria

• Patients who voluntarily participate in the study, completely understand the study, and voluntarily sign the informed consent form (ICF).
• Female, ≥ 18 and ≤ 75 years of age at the time of signing the ICF.
• ECOG（Eastern Cooperative Oncology Group） performance status 0 or 1.
• Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.